Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 4,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00. Following the transaction, the director now owns 9,704 shares of the company's stock, valued at approximately $1,366,129.12. The trade was a 29.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Gail Boxer Marcus also recently made the following trade(s):

• On Wednesday, March 12th, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $147.69, for a total value of $590,760.00.

Natera Price Performance

NTRA traded down $5.18 during trading on Tuesday, hitting $133.08. The company's stock had a trading volume of 732,354 shares, compared to its average volume of 1,378,458. The firm's 50 day moving average price is $156.27 and its two-hundred day moving average price is $151.65. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $17.99 billion, a price-to-earnings ratio of -75.21 and a beta of 1.80. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on NTRA shares. Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Royal Bank of Canada began coverage on Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. Morgan Stanley boosted their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. Finally, Barclays started coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price on the stock. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and an average target price of $178.12.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NTRA. The Manufacturers Life Insurance Company raised its position in shares of Natera by 87.3% during the third quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company's stock worth $8,621,000 after acquiring an additional 31,649 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Natera by 5.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,339 shares of the medical research company's stock worth $3,344,000 after purchasing an additional 1,263 shares during the period. Captrust Financial Advisors raised its holdings in Natera by 108.7% during the 3rd quarter. Captrust Financial Advisors now owns 5,689 shares of the medical research company's stock worth $722,000 after purchasing an additional 2,963 shares during the last quarter. Paloma Partners Management Co acquired a new position in Natera during the 3rd quarter valued at about $238,000. Finally, Benjamin Edwards Inc. boosted its stake in shares of Natera by 15,167.3% in the 3rd quarter. Benjamin Edwards Inc. now owns 7,481 shares of the medical research company's stock valued at $950,000 after purchasing an additional 7,432 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.